ZIMV vs. SONX, BIOL, SDCCQ, XRAY, NVST, FUSN, ADUS, NEO, GLPG, and LMAT
Should you be buying ZimVie stock or one of its competitors? The main competitors of ZimVie include Sonendo (SONX), BIOLASE (BIOL), SmileDirectClub (SDCCQ), DENTSPLY SIRONA (XRAY), Envista (NVST), Fusion Pharmaceuticals (FUSN), Addus HomeCare (ADUS), NeoGenomics (NEO), Galapagos (GLPG), and LeMaitre Vascular (LMAT). These companies are all part of the "medical" sector.
ZimVie (NASDAQ:ZIMV) and Sonendo (NYSE:SONX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.
95.6% of ZimVie shares are owned by institutional investors. Comparatively, 28.7% of Sonendo shares are owned by institutional investors. 3.0% of ZimVie shares are owned by company insiders. Comparatively, 6.4% of Sonendo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, ZimVie had 3 more articles in the media than Sonendo. MarketBeat recorded 3 mentions for ZimVie and 0 mentions for Sonendo. ZimVie's average media sentiment score of 1.77 beat Sonendo's score of 0.00 indicating that ZimVie is being referred to more favorably in the media.
Sonendo received 10 more outperform votes than ZimVie when rated by MarketBeat users. Likewise, 40.74% of users gave Sonendo an outperform vote while only 7.14% of users gave ZimVie an outperform vote.
ZimVie has a net margin of -56.31% compared to Sonendo's net margin of -130.16%. ZimVie's return on equity of 2.01% beat Sonendo's return on equity.
Sonendo has lower revenue, but higher earnings than ZimVie. ZimVie is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.
ZimVie has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500. Comparatively, Sonendo has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.
ZimVie currently has a consensus target price of $17.33, indicating a potential upside of 4.10%. Sonendo has a consensus target price of $1.88, indicating a potential upside of 2,085.31%. Given Sonendo's stronger consensus rating and higher probable upside, analysts clearly believe Sonendo is more favorable than ZimVie.
Summary
ZimVie beats Sonendo on 9 of the 17 factors compared between the two stocks.
Get ZimVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIMV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZIMV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
